Junjie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.
Junjie Li, MD
Advertisement
Articles by Junjie Li, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5